High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob LöwenbergGert J. OssenkoppeleWim van PuttenHarry C. SchoutenCarlos GrauxAugustin FerrantPieter SonneveldJohan MaertensMojca Jongen‐LavrencicMarie von Lilienfeld‐ToalBart J. BiemondEdo VellengaMarinus van Marwijk KooyLeo F. VerdonckJoachim BeckHartmut DöhnerAloïs GratwohlThomas PabstGregor Verhoef
Abstract
In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.)
Metrics
Citation History
Topics
Related Documents
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Outcome analysis of acute myeloid leukemia patients treated with high dose daunorubicin
Roya DolatkhahEffat Irani JamAlireza NikanfarAli EsfahaniSayed Hadi ChavooshiBabak NejatiZohreh Sanaat
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
Je‐Hwan LeeYoung‐Don JooHawk KimSung Hwa BaeMin Kyoung KimDae Young ZangJunglim LeeGyeong Won LeeJung‐Hee LeeJae-Hoo ParkDae‐Young KimWon-Sik LeeHun Mo RyooMyung Soo HyunHyo Jung KimYoung Joo MinYae-Eun JangKyoo‐Hyung Leefor the Cooperative Study Group A for Hematology
Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older
Claude GardinSylvie ChevretCécile PautasPascal TurlureEmmanuel RaffouxXavier ThomasBruno QuesnelThierry de RevelStéphane de BottonNathalie GachardAline RennevilleNicolas BoisselClaude PreudhommeChristine TerréPierre FenauxDominique BordessouleKarine Celli‐LebrasSylvie CastaignéHervé Dombret
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
Hannah AsghariJeffrey E. Lancet